Skip to main content
Equibles
DMII logo

DMII · Drugs Made In America Acquisition II Corp.

Track DMII — free

Use DMII with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DMII.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.17 -0.01 (-0.05%) At close · Sep 18
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 14, 2026
Market Cap
$647.19M
Shares
63.70M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.17 Open$10.18 Day$10.17–10.18 Available close range$9.87–10.18 Avg vol 30d76K Short int119K · 0.2% float · 1.9d Short vol0% DataDec 2025–Sep 2026 Filing10-Q · Aug 14

The closing range uses available history since Dec 3, 2025; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$13.02M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
49.7
Trailing earnings · reciprocal yield 2.0%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$275,026
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.7%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
0.2%
Latest settlement · 1.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very Low
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg +0%
above
RSI (14) 59
neutral
MACD trend Negative
52-week position 97%
near high
Momentum
relative strength
Strong
1-month return 0%
trailing
6-month return +2%
trailing
YTD return +3%
this year
Relative strength −18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+2% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.19% of float · ▼ -2.2% MoM · 1.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
84 holders — near 1-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very Low
Volatility 2%
annualized · 1-yr
Max drawdown −1%
past year
ATR 0.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+0% Bullish
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
97% Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+2% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.19% of float · ▼ -2.2% MoM · 1.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
84 holders — near 1-yr high, broad support
Price context
position in its available closing range
Range low $10 Now $10 · 97% Range high $10
vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Shell Companies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DMII
Drugs Made In America Acquisition II Corp.
this stock
$647.19M +2.7% — — 0.2%
CLUS
Cluster Group Holdings Ltd Co
 $8.00B — — — —
CCXI
Churchill Capital Corp XI
 $684.55M — — — 6.7%
EVAC
EQV Ventures Acquisition Corp. II
 $602.01M +2.7% — — 0.0%
BCSS
Bain Capital GSS Investment Corp.
 $600.94M +2.1% — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
84
% held
137.5%
Net QoQ
-577.6K sh
Top holder
Karpus Management, Inc.
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
119.3K
Days to cover
1.9d
Change
-2.6K sh
View
Short Volume
Short vol %
0%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
30.7K
Value
$311.0K
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
88.3%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$4.2M
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
8
View

Performance

5D 20D 120D MTD YTD
DMII +0.1% +0.3% +2.3% +0.2% +2.7%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY +0.4% +0.4% -17.8% +0.9% -9.0%
Key facts CIK 2040475 CUSIP G2851K104 13F (30d) 2 filings 2 filers